Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation (NCT05474664) | Clinical Trial Compass
CompletedPhase 2
Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation
South Korea19 participantsStarted 2022-10-03
Plain-language summary
This study is phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after Fontan operation.
Who can participate
Age range4 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* history of protein-losing enteropathy after Fontan operation
* more than 6 months after Fontan operation
* more than 3 months of protein-losing enteropathy history (ascites, edema, diarrhea, etc) and less than 3.0 mg/dL of serum albumin without evidence of renal or liver disease
Exclusion Criteria:
* inability to take oral camostate mesylate
* hypersensitivity to camostate mesylate
* patients with taking similar medication or prohibited combination drug
* patients participating in other clinical trials
* patients with diet limitation
* patients with genetic disease such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption